Attoquant Diagnostics
Attoquant Diagnostics is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema
Sponsor Pharvaris Netherlands B.V.
- Start (EU)
- Latest update
- Estimated end
A Randomised, Double-Blind, Placebo Controlled, Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Repeat Dose of Inhaled ETD001 in People with Cystic Fibrosis
Sponsor Enterprise Therapeutics Limited
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Twenty of 21 study centres across France, Germany, Italy, and the United Kingdom consented at least one participant.
- Of 57 randomized participants, 30 were randomized in Germany, 11 in Italy, 10 in the United Kingdom, and 6 in France.
- The 28-day treatment duration precluded direct assessment of longer-term clinical outcomes.
- The study excluded individuals receiving CFTR modulators, so applicability to a broader cystic fibrosis population requires further evaluation.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema due to C1 Inhibitor Deficiency
Sponsor Pharvaris Netherlands B.V.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Attoquant Diagnostics?
The 2026-10-09 snapshot links Attoquant Diagnostics to 3 distinct CTIS trials. Recorded services include Laboratory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Attoquant Diagnostics?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Immunology, Allergy, Respiratory. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Attoquant Diagnostics conducted?
The linked trials record locations in 14 countries, including Germany, France, Italy, Austria, Bulgaria. These are trial locations, not confirmed office locations or countries where Attoquant Diagnostics delivered services.
What can this page tell me about Attoquant Diagnostics's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Attoquant Diagnostics. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Attoquant Diagnostics GmbH